The TIPI Study

The purpose of this research is to find out if a single dose of pre-travel vaccination with BCG (a living organism preparation) can lessen Tuberculosis (TB) infection by producing an immune response (development of TB fighter cells within the body) when given to adults traveling to countries with a high burden of TB. BCG will be compared with a placebo (an inactive vaccine). Participants will be randomly assigned (this is like a coin flip) to receive BCG vaccine or placebo.

• Participant is age 18-65
• Participant has no known history of Mtb infection or HIV infection
• Participant has no prior history of BCG vaccination, or previous receipt of an investigational Mtb vaccine
• Participant is assessed to be at risk for TB exposure (particularly drug resistant TB) during planned travel and has planned to work in high TB burden countries for a duration of >4 weeks and <6 months for HCW, or ≥6 months and ≤2.5 years if long term traveler and/or/HCW
• Participant presents for study screening at least 4 weeks prior to travel departure